astrazeneca ceo awaits diagnosis on covid-19 trial participant who developed neurological condition
Published 3 years ago • 4K plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
3:14
astrazeneca ceo addresses coronavirus trial pause
-
7:47
who: delay in astrazeneca coronavirus vaccine trial is a 'wake up call'
-
7:27
astrazeneca ceo on covid-19 vaccine efforts, barda funding and more
-
4:48
astrazeneca executive explains positive covid-19 vaccine results
-
8:14
astrazeneca down after report that covid-19 vaccine is put on hold
-
10:24
key researcher in astrazeneca's oxford vaccine breaks down trials data
-
6:16
ceo pascal soriot on covid-19 vaccine - cnn
-
32:57
understanding covid-19
-
1:39
astrazeneca and u.s. strike deal to develop covid-19 antibody drug supply
-
4:25
jim cramer on astrazeneca's communication regarding trial pause: total amateur hour
-
4:43
astrazeneca pause is a good thing: stat news' adam feuerstein
-
6:05
astrazeneca u.s. president explains trial data, plans for filing for u.s. approval
-
1:58
oxford-astrazeneca vaccine shows positive immune response in early study
-
0:33
astrazeneca surges after hhs provides $500 million for covid-19 antibody treatment development
-
3:17
oxford/astrazeneca covid-19 vaccine can be up to 90% effective
-
4:57
oxford professor on the timeline of the astrazeneca covid-19 vaccine
-
2:27
astrazeneca vaccine found to be 79% effective in u.s. trial
-
3:10
astrazeneca revises covid vaccine data with lower efficacy rate after accuracy questions
-
2:42
could astrazeneca's pause on covid-19 vaccine trial impact other trials?
-
6:20
who on oxford-astrazeneca coronavirus vaccine data: it is good news
-
3:05
astrazeneca vaccine found to be 79% effective in u.s. study
-
4:12
astrazeneca and johnson & johnson resume phase 3 vaccine trials